HRP20010619A2 - Hetrocyclic benzenesulphonamide compounds as bradykinine antagonists - Google Patents

Hetrocyclic benzenesulphonamide compounds as bradykinine antagonists Download PDF

Info

Publication number
HRP20010619A2
HRP20010619A2 HR20010619A HRP20010619A HRP20010619A2 HR P20010619 A2 HRP20010619 A2 HR P20010619A2 HR 20010619 A HR20010619 A HR 20010619A HR P20010619 A HRP20010619 A HR P20010619A HR P20010619 A2 HRP20010619 A2 HR P20010619A2
Authority
HR
Croatia
Prior art keywords
methyl
group
substance
yield
procedure
Prior art date
Application number
HR20010619A
Other languages
English (en)
Croatian (hr)
Inventor
Pierre Dodey
Martine Barth
Michel Bondoux
Original Assignee
Fournier Ind Et Sante French L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Ind Et Sante French L filed Critical Fournier Ind Et Sante French L
Publication of HRP20010619A2 publication Critical patent/HRP20010619A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
HR20010619A 1999-02-26 2000-02-17 Hetrocyclic benzenesulphonamide compounds as bradykinine antagonists HRP20010619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9902412A FR2790260B1 (fr) 1999-02-26 1999-02-26 Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
PCT/FR2000/000396 WO2000050418A1 (fr) 1999-02-26 2000-02-17 Composes heterocycliques de benzenesulfonamide en tant qu'antagonistes de la bradykinine

Publications (1)

Publication Number Publication Date
HRP20010619A2 true HRP20010619A2 (en) 2002-08-31

Family

ID=9542576

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010619A HRP20010619A2 (en) 1999-02-26 2000-02-17 Hetrocyclic benzenesulphonamide compounds as bradykinine antagonists

Country Status (31)

Country Link
US (1) US6479515B1 (de)
EP (1) EP1155013B1 (de)
JP (1) JP4564666B2 (de)
KR (1) KR20010102057A (de)
CN (1) CN1340050A (de)
AR (1) AR022754A1 (de)
AT (1) ATE245640T1 (de)
AU (1) AU2809600A (de)
BG (1) BG105840A (de)
BR (1) BR0008221A (de)
CA (1) CA2371853C (de)
CZ (1) CZ303169B6 (de)
DE (1) DE60004017T2 (de)
DK (1) DK1155013T3 (de)
EE (1) EE04839B1 (de)
ES (1) ES2202059T3 (de)
FR (1) FR2790260B1 (de)
HK (1) HK1041267A1 (de)
HR (1) HRP20010619A2 (de)
HU (1) HUP0200281A3 (de)
ID (1) ID29914A (de)
IL (1) IL144720A0 (de)
MX (1) MXPA01008672A (de)
NO (1) NO20014048L (de)
NZ (1) NZ513732A (de)
PL (1) PL199209B1 (de)
PT (1) PT1155013E (de)
SK (1) SK286710B6 (de)
TN (1) TNSN00031A1 (de)
WO (1) WO2000050418A1 (de)
ZA (1) ZA200106250B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6809093B2 (en) * 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1572678A4 (de) * 2002-12-19 2008-05-07 Elan Pharm Inc Substituierte n-phenylsulfonamide alsbradykininantagonisten
EP1633743A1 (de) * 2003-04-10 2006-03-15 Amgen, Inc. Cyclische aminderivative und deren verwendung bei der behandlung von durch bradykinin vermittelten entzündlichen erkrankungen
JP2006525361A (ja) * 2003-05-02 2006-11-09 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体アンタゴニストとしての選択された置換ピラゾール誘導体および関連化合物
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
EP1633349A1 (de) * 2003-05-02 2006-03-15 Elan Pharmaceuticals, Inc. 4-bromo-5- (2-chlorobenzoylamino)-1h-pyrazol-3-carbonsäure (1-(aminocarbonyl) eth-1-yl) amid-derivate und verwandte verbindungen als bradykinin-b1-rezeptorantagonisten zur behandlung von entzündlichen erkrankungen
RU2462464C2 (ru) * 2006-09-29 2012-09-27 Грюненталь Гмбх Замещенные сульфамидные производные
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
BR112014021498A2 (pt) * 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
AR113839A1 (es) 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
US20250268887A1 (en) 2022-03-25 2025-08-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
ES3062067T3 (en) 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617183A1 (de) 1985-11-16 1987-05-27 Bayer Ag Substituierte benzylether
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
JPH06508116A (ja) 1991-04-01 1994-09-14 コルテク，インコーポレイテッド ブラジキニンアンタゴニスト
US5610140A (en) 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
TW258739B (de) 1992-04-04 1995-10-01 Hoechst Ag
US5610142A (en) 1992-10-08 1997-03-11 Scios Inc. Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
US5510380A (en) 1993-02-19 1996-04-23 Sterling Winthrop, Inc. Nonpeptide bradykinin antagonists
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
ES2218554T3 (es) 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
FR2735128B1 (fr) 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
GB9519077D0 (en) 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2756562B1 (fr) * 1996-12-04 1999-01-08 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2765222B1 (fr) 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique

Also Published As

Publication number Publication date
BR0008221A (pt) 2001-11-20
JP4564666B2 (ja) 2010-10-20
AR022754A1 (es) 2002-09-04
SK11922001A3 (sk) 2001-12-03
NO20014048D0 (no) 2001-08-20
HUP0200281A2 (en) 2002-06-29
NZ513732A (en) 2001-09-28
ES2202059T3 (es) 2004-04-01
IL144720A0 (en) 2002-06-30
EP1155013B1 (de) 2003-07-23
ZA200106250B (en) 2002-07-30
EE04839B1 (et) 2007-06-15
CZ303169B6 (cs) 2012-05-09
FR2790260B1 (fr) 2001-05-04
CA2371853C (en) 2009-09-29
PL350234A1 (en) 2002-11-18
NO20014048L (no) 2001-08-20
PL199209B1 (pl) 2008-08-29
CA2371853A1 (en) 2000-08-31
CN1340050A (zh) 2002-03-13
AU2809600A (en) 2000-09-14
MXPA01008672A (es) 2003-06-24
DE60004017D1 (de) 2003-08-28
CZ20013067A3 (cs) 2001-11-14
WO2000050418A9 (fr) 2001-02-22
FR2790260A1 (fr) 2000-09-01
EE200100444A (et) 2002-12-16
ID29914A (id) 2001-10-25
SK286710B6 (sk) 2009-03-05
HUP0200281A3 (en) 2003-05-28
DK1155013T3 (da) 2003-11-17
JP2002537392A (ja) 2002-11-05
DE60004017T2 (de) 2004-07-01
ATE245640T1 (de) 2003-08-15
HK1041267A1 (zh) 2002-07-05
BG105840A (en) 2002-04-30
TNSN00031A1 (fr) 2005-11-10
US6479515B1 (en) 2002-11-12
PT1155013E (pt) 2003-12-31
KR20010102057A (ko) 2001-11-15
EP1155013A1 (de) 2001-11-21
WO2000050418A1 (fr) 2000-08-31

Similar Documents

Publication Publication Date Title
HRP20010619A2 (en) Hetrocyclic benzenesulphonamide compounds as bradykinine antagonists
DE69709727T2 (de) Parazinon thrombin inhibitoren
EP1188754B1 (de) Substituierte pyrazol-derivate
KR20030070080A (ko) 엔-(페닐술포닐) 글리신 유도체와 이들의 치료적 용도
RU2097378C1 (ru) ПРОИЗВОДНЫЕ N-АЦИЛ- α -АМИНОКИСЛОТЫ ИЛИ ИХ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ПРОСТЫЕ ИЛИ СЛОЖНЫЕ ЭФИРЫ, АМИДЫ ИЛИ ГИДРАТЫ И КОМПОЗИЦИЯ ИНГИБИРУЮЩАЯ СВЯЗЫВАНИЕ АДГЕЗИВНЫХ ПРОТЕИНОВ С ТРОМБОЦИТАМИ И АГРЕГАЦИЮ ТРОМБОЦИТОВ
TW234717B (en) 1-[2-(arylsulfonylamine)-1-oxoethyl]piperidine derivatives, their preparation and therapeutic applications
SK286779B6 (sk) N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie
CZ82195A3 (en) Inhibitors of farnesyl-protein transferase containing imidazole nucleus
JPH01221357A (ja) ペプチジル複素環
DE69912429T2 (de) Hydrazin derivate
DE4243858A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH05504968A (ja) グリシンアミド誘導体、その製造及びそれを含む医薬品
DE19939910A1 (de) Neue Verbindungen, die Tryptase-Aktivität hemmen
JP2000514818A (ja) ブラジキニン拮抗剤としてのｎ−ベンゼンスルホニル−ｌ−プロリン誘導体
EP0252727A1 (de) Aminosäure-Derivate
EP1318996B1 (de) Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
DE69818051T2 (de) Neue N-(Benzolsulfonyl)-L-prolin-Verbindungen, Verfahren zu ihrer Herstellung und therapeutische Verwendung
EP0882699A1 (de) Aminoverbindungen und angiotensin iv rezeptor agonisten
EP0653434A1 (de) Glucosaminderivate, deren Herstellung und Zwischenprodukte
USH1729H (en) Method for preparing compounds employing solid phase synthesis and novel linker-resin
HK1051500B (en) Cell adhesion inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20030131

Year of fee payment: 4

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn